[Mini-transplantation from HLA-mismatched donors].
Bone marrow transplantation(BMT) from genotypically human leukocyte antigen (HLA)-matched siblings improves long-term survival in patients with hematologic malignancies. However, more than 70% of patients who could benefit from allogeneic BMT do not have a matched sibling donor. Furthermore, allogeneic BMT has been limited to young patients because of the increased risk for regimen-related toxicity and graft-versus-host disease(GVHD) that occurs with increasing age. HLA-haploidentical minitransplantation may solve these problems. In minitransplants using a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and methylprednisolone, we showed that minitransplantation from HLA-haploidentical related donors was possible.
D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000517:prevention & control; D006680:HLA Antigens; D019337:Hematologic Neoplasms / Q000628:therapy; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000961:Antilymphocyte Serum; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine